Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma.
Pönisch W et al. J Cancer Res Clin Oncol. 2014 Jun 19. [Epub ahead of print].

The choice of regimens based on bortezomib for patients with newly diagnosed multiple myeloma.
He J et al. PLoS One. 2014 Jun 11;9(6):e99174. doi: 10.1371/journal.pone.0099174. eCollection 2014.

Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial.
Herbert KE et al. Bone Marrow Transplant. 2014 Jun 2. doi: 10.1038/bmt.2014.112. [Epub ahead of print].

Role of plerixafor for autologous stem cell mobilization with vinorelbine chemotherapy and G-CSF in patients with myeloma; a phase II study (PAV-trial).
Schmid A et al. Leuk Lymphoma. 2014 Jun 2:1-24. [Epub ahead of print].

Similar dynamics of intraapheresis autologous CD34+ recruitment and collection efficiency in patients undergoing mobilization with or without plerixafor.
Schade H et al. Transfusion. 2014 Jun 19. doi: 10.1111/trf.12761. [Epub ahead of print].

Evaluation of the spectra Optia® mononuclear cell collection procedure in multiple myeloma patients.
Long G et al. J Clin Apher. 2014 Jun 19. doi: 10.1002/jca.21341. [Epub ahead of print].

Phase IIa cross-over study of propylene glycol-free melphalan (LGD-353) and alkeran in multiple myeloma autologous transplantation.
Aljitawi OS et al. Bone Marrow Transplant. 2014 Jun 9. doi: 10.1038/bmt.2014.120. [Epub ahead of print].

Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients.
Takashima S et al. Int J Hematol. 2014 Jun 14. [Epub ahead of print].

High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
Cook G et al. Lancet Oncol. 2014 Jun 16. pii: S1470-2045(14)70245-1. doi: 10.1016/S1470-2045(14)70245-1. [Epub ahead of print].

Modified Bortezomib, Adriamycin and Dexamethasone (PAD) Regimen in Advanced Multiple Myeloma.
Zhang Y et al. Pathol Oncol Res. 2014 Jun 19. [Epub ahead of print].

Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival.
Kiba T et al. BMC Cancer. 2014 Jun 21;14(1):462. [Epub ahead of print].